ArticleEMBO molecular medicine2026
Betrixaban activates cGAS-STING to promote antitumor immunity without pathological inflammation.
Yang Zhao, Xingyu Chen, LiRui Tang, Hanjie Liu, Boming Kang, Shuailong Zheng, Songying Ouyang, Yunfei Xie, Fuping You
Abstract read
In one paragraphArticle in EMBO molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Yang Zhao *Institute of Systems Biomedicine, Department of Immunology, School of Basic Medical Sciences, Beijing Key Laboratory of Tumor Systems Biology, NHC Key Laboratory of Medical Immunology, Peking University Health Science Center, Beijing, China. 2311210031@stu.pku.edu.cn.ORCID 0009-0002-1282-8975 Xingyu Chen *Institute of Systems Biomedicine, Department of Immunology, School of Basic Medical Sciences, Beijing Key Laboratory of Tumor Systems Biology, NHC Key Laboratory of Medical Immunology, Peking University Health Science Center, Beijing, China.
LiRui TangKey Laboratory of Microbial Pathogenesis and Interventions of Fujian Province University, the Key Laboratory of Innate Immune Biology of Fujian Province, Biomedical Research Center of South China, College of Life Sciences, Fujian Normal University, Fuzhou, China.
Hanjie LiuDepartment of Endocrinology, Yuquan Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.ORCID 0009-0005-6495-4705 Boming KangInstitute of Systems Biomedicine, Department of Immunology, School of Basic Medical Sciences, Beijing Key Laboratory of Tumor Systems Biology, NHC Key Laboratory of Medical Immunology, Peking University Health Science Center, Beijing, China.
Shuailong ZhengKey Laboratory of Swine Genetics and Breeding of Ministry of Agriculture and Rural Affairs, Huazhong Agricultural University, Wuhan, China.
Songying OuyangKey Laboratory of Microbial Pathogenesis and Interventions of Fujian Province University, the Key Laboratory of Innate Immune Biology of Fujian Province, Biomedical Research Center of South China, College of Life Sciences, Fujian Normal University, Fuzhou, China. ouyangsy@fjnu.edu.cn.ORCID 0000-0002-1120-1524 Yunfei Xie *Institute of Systems Biomedicine, Department of Immunology, School of Basic Medical Sciences, Beijing Key Laboratory of Tumor Systems Biology, NHC Key Laboratory of Medical Immunology, Peking University Health Science Center, Beijing, China. qhx18@tsinghua.org.cn.
Fuping YouInstitute of Systems Biomedicine, Department of Immunology, School of Basic Medical Sciences, Beijing Key Laboratory of Tumor Systems Biology, NHC Key Laboratory of Medical Immunology, Peking University Health Science Center, Beijing, China. fupingyou@hsc.pku.edu.cn.ORCID 0000-0002-7444-729X Funding
MOST | National Key Research and Development Program of China (NKPs) 2021YFC2302602MOST | National Natural Science Foundation of China (NSFC) 8235071080; 3247080250; 31570891; 31872736; 32022028; 81991505; 82201928| Natural Science Foundation of Beijing Municipality () Z210014
6 · The paper itselfAbstract
Effective cancer immunotherapy requires enhancing tumor-targeted immune responses while limiting pathological inflammation, highlighting an urgent need for single agents that can achieve this balance. Here, we reported that Betrixaban (BT), an FDA-approved Factor Xa inhibitor, functioned as a dual immunomodulator that enhanced antitumor immune responses and suppressed hyperinflammation. BT enhanced innate tumor sensing and adaptive immune responses, partly via epigenetic modulation. In mouse tumor models, BT treatment inhibited tumor growth, accompanied by increased infiltration of activated CD8
Indexed as
BenzamidesMembrane ProteinsNeoplasmsNucleotidyltransferasesPyridinesAnimalsCell Line, TumorcGAS-STING Signaling PathwayCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseFemaleHumansImmunotherapyInflammationMiceMice, Inbred C57BLSTING ProteinBenzamidescGAS protein, mouseCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseMembrane ProteinsNucleotidyltransferasesPyridinesSting1 protein, mouseSTING Protein
Identifiers
PMID42135568
PMCPMC13269763
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390